LncRNA and its role in gastric cancer immunotherapy
Gastric cancer (GC) is a potential dominant disease in tumor immunotherapy checkpoint inhibitors, and adoptive cell therapy have brought great hope to GC patients. However, only some patients with GC can benefit from immunotherapy, and some patients develop drug resistance. More and more studies hav...
Main Authors: | Qiang Zhang, Chuanchi Wang, Yan Yang, Ruihan Xu, Ziyun Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Cell and Developmental Biology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcell.2023.1052942/full |
Similar Items
-
Upregulation of BCAM and its sense lncRNA BAN are associated with gastric cancer metastasis and poor prognosis
by: Juan Jin, et al.
Published: (2020-04-01) -
Editorial: lncRNA in plants: function, mechanisms and applications
by: Jun Cui
Published: (2023-06-01) -
The value of metabolic LncRNAs in predicting prognosis and immunotherapy efficacy of gastric cancer
by: Peizhun Du, et al.
Published: (2023-01-01) -
Low expression of lncRNA APTR promotes gastric cancer progression
by: Aigang Ren, et al.
Published: (2022-11-01) -
The novel lncRNA p4516 acts as a prognostic biomarker promoting gastric cancer cell proliferation and metastasis
by: Nie ML, et al.
Published: (2019-06-01)